NPJ VACCINES 润色咨询

npj Vaccines

出版年份：2016 年文章数：385 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：4.5% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2189864, encodeId=39292189864b6, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：vaccine;immunology<br>经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0dc9186564, createdName=ms9000001531261919, createdTime=Wed Feb 28 11:31:59 CST 2024, time=2024-02-28, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2174128, encodeId=949821e41281d, content=审稿速度:24.0 | 投稿命中率:25.0<br>经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e522550600, createdName=1253f878m25(暂无昵称), createdTime=Sun Dec 10 22:20:04 CST 2023, time=2023-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1220774, encodeId=1c181220e7421, content=请问这个期刊接收兽医领域的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc36406249, createdName=ms9000000094430055, createdTime=Wed May 18 22:15:22 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198701, encodeId=44b11198e0136, content=为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EC68C3C3E967114681E7C61FF972B471/100, createdBy=0d342025844, createdName=汤圆-, createdTime=Wed Mar 02 13:20:58 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107493, encodeId=1731110e493d7, content=评审和期刊编辑要求我补实验，就一定要补么，不补行不行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107494, encodeId=db95110e494e4, content=对于审稿人好的意见也要回复么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602494, encodeId=55eb60249406, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：NPJ系列，是新培育出来的，有前途, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 18 13:02:46 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572669, encodeId=a8fa5e26698b, content=已经破5了，超过vaccine，估计疫苗学以后就是这个top了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851026, encodeId=21bf85102651, content=文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec45414146, createdName=ms3214948925389860, createdTime=Thu Apr 25 14:12:58 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2024-02-28 ms9000001531261919 来自马里兰

    审稿速度:12.0 | 投稿命中率:25.0
    偏重的研究方向：vaccine;immunology
    经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2189864, encodeId=39292189864b6, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：vaccine;immunology<br>经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0dc9186564, createdName=ms9000001531261919, createdTime=Wed Feb 28 11:31:59 CST 2024, time=2024-02-28, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2174128, encodeId=949821e41281d, content=审稿速度:24.0 | 投稿命中率:25.0<br>经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e522550600, createdName=1253f878m25(暂无昵称), createdTime=Sun Dec 10 22:20:04 CST 2023, time=2023-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1220774, encodeId=1c181220e7421, content=请问这个期刊接收兽医领域的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc36406249, createdName=ms9000000094430055, createdTime=Wed May 18 22:15:22 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198701, encodeId=44b11198e0136, content=为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EC68C3C3E967114681E7C61FF972B471/100, createdBy=0d342025844, createdName=汤圆-, createdTime=Wed Mar 02 13:20:58 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107493, encodeId=1731110e493d7, content=评审和期刊编辑要求我补实验，就一定要补么，不补行不行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107494, encodeId=db95110e494e4, content=对于审稿人好的意见也要回复么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602494, encodeId=55eb60249406, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：NPJ系列，是新培育出来的，有前途, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 18 13:02:46 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572669, encodeId=a8fa5e26698b, content=已经破5了，超过vaccine，估计疫苗学以后就是这个top了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851026, encodeId=21bf85102651, content=文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec45414146, createdName=ms3214948925389860, createdTime=Thu Apr 25 14:12:58 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2023-12-10 1253f878m25(暂无昵称) 来自北京

    审稿速度:24.0 | 投稿命中率:25.0
    经验分享：无

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2189864, encodeId=39292189864b6, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：vaccine;immunology<br>经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0dc9186564, createdName=ms9000001531261919, createdTime=Wed Feb 28 11:31:59 CST 2024, time=2024-02-28, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2174128, encodeId=949821e41281d, content=审稿速度:24.0 | 投稿命中率:25.0<br>经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e522550600, createdName=1253f878m25(暂无昵称), createdTime=Sun Dec 10 22:20:04 CST 2023, time=2023-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1220774, encodeId=1c181220e7421, content=请问这个期刊接收兽医领域的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc36406249, createdName=ms9000000094430055, createdTime=Wed May 18 22:15:22 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198701, encodeId=44b11198e0136, content=为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EC68C3C3E967114681E7C61FF972B471/100, createdBy=0d342025844, createdName=汤圆-, createdTime=Wed Mar 02 13:20:58 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107493, encodeId=1731110e493d7, content=评审和期刊编辑要求我补实验，就一定要补么，不补行不行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107494, encodeId=db95110e494e4, content=对于审稿人好的意见也要回复么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602494, encodeId=55eb60249406, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：NPJ系列，是新培育出来的，有前途, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 18 13:02:46 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572669, encodeId=a8fa5e26698b, content=已经破5了，超过vaccine，估计疫苗学以后就是这个top了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851026, encodeId=21bf85102651, content=文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec45414146, createdName=ms3214948925389860, createdTime=Thu Apr 25 14:12:58 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2022-05-18 ms9000000094430055

    请问这个期刊接收兽医领域的文章吗？

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2189864, encodeId=39292189864b6, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：vaccine;immunology<br>经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0dc9186564, createdName=ms9000001531261919, createdTime=Wed Feb 28 11:31:59 CST 2024, time=2024-02-28, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2174128, encodeId=949821e41281d, content=审稿速度:24.0 | 投稿命中率:25.0<br>经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e522550600, createdName=1253f878m25(暂无昵称), createdTime=Sun Dec 10 22:20:04 CST 2023, time=2023-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1220774, encodeId=1c181220e7421, content=请问这个期刊接收兽医领域的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc36406249, createdName=ms9000000094430055, createdTime=Wed May 18 22:15:22 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198701, encodeId=44b11198e0136, content=为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EC68C3C3E967114681E7C61FF972B471/100, createdBy=0d342025844, createdName=汤圆-, createdTime=Wed Mar 02 13:20:58 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107493, encodeId=1731110e493d7, content=评审和期刊编辑要求我补实验，就一定要补么，不补行不行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107494, encodeId=db95110e494e4, content=对于审稿人好的意见也要回复么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602494, encodeId=55eb60249406, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：NPJ系列，是新培育出来的，有前途, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 18 13:02:46 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572669, encodeId=a8fa5e26698b, content=已经破5了，超过vaccine，估计疫苗学以后就是这个top了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851026, encodeId=21bf85102651, content=文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec45414146, createdName=ms3214948925389860, createdTime=Thu Apr 25 14:12:58 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2022-03-02 汤圆-

    为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2189864, encodeId=39292189864b6, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：vaccine;immunology<br>经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0dc9186564, createdName=ms9000001531261919, createdTime=Wed Feb 28 11:31:59 CST 2024, time=2024-02-28, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2174128, encodeId=949821e41281d, content=审稿速度:24.0 | 投稿命中率:25.0<br>经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e522550600, createdName=1253f878m25(暂无昵称), createdTime=Sun Dec 10 22:20:04 CST 2023, time=2023-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1220774, encodeId=1c181220e7421, content=请问这个期刊接收兽医领域的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc36406249, createdName=ms9000000094430055, createdTime=Wed May 18 22:15:22 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198701, encodeId=44b11198e0136, content=为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EC68C3C3E967114681E7C61FF972B471/100, createdBy=0d342025844, createdName=汤圆-, createdTime=Wed Mar 02 13:20:58 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107493, encodeId=1731110e493d7, content=评审和期刊编辑要求我补实验，就一定要补么，不补行不行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107494, encodeId=db95110e494e4, content=对于审稿人好的意见也要回复么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602494, encodeId=55eb60249406, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：NPJ系列，是新培育出来的，有前途, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 18 13:02:46 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572669, encodeId=a8fa5e26698b, content=已经破5了，超过vaccine，估计疫苗学以后就是这个top了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851026, encodeId=21bf85102651, content=文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec45414146, createdName=ms3214948925389860, createdTime=Thu Apr 25 14:12:58 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2021-12-28 MS54455111222

    评审和期刊编辑要求我补实验，就一定要补么，不补行不行？

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2189864, encodeId=39292189864b6, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：vaccine;immunology<br>经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0dc9186564, createdName=ms9000001531261919, createdTime=Wed Feb 28 11:31:59 CST 2024, time=2024-02-28, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2174128, encodeId=949821e41281d, content=审稿速度:24.0 | 投稿命中率:25.0<br>经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e522550600, createdName=1253f878m25(暂无昵称), createdTime=Sun Dec 10 22:20:04 CST 2023, time=2023-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1220774, encodeId=1c181220e7421, content=请问这个期刊接收兽医领域的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc36406249, createdName=ms9000000094430055, createdTime=Wed May 18 22:15:22 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198701, encodeId=44b11198e0136, content=为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EC68C3C3E967114681E7C61FF972B471/100, createdBy=0d342025844, createdName=汤圆-, createdTime=Wed Mar 02 13:20:58 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107493, encodeId=1731110e493d7, content=评审和期刊编辑要求我补实验，就一定要补么，不补行不行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107494, encodeId=db95110e494e4, content=对于审稿人好的意见也要回复么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602494, encodeId=55eb60249406, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：NPJ系列，是新培育出来的，有前途, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 18 13:02:46 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572669, encodeId=a8fa5e26698b, content=已经破5了，超过vaccine，估计疫苗学以后就是这个top了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851026, encodeId=21bf85102651, content=文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec45414146, createdName=ms3214948925389860, createdTime=Thu Apr 25 14:12:58 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2021-12-28 Mia

    对于审稿人好的意见也要回复么？

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2189864, encodeId=39292189864b6, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：vaccine;immunology<br>经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0dc9186564, createdName=ms9000001531261919, createdTime=Wed Feb 28 11:31:59 CST 2024, time=2024-02-28, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2174128, encodeId=949821e41281d, content=审稿速度:24.0 | 投稿命中率:25.0<br>经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e522550600, createdName=1253f878m25(暂无昵称), createdTime=Sun Dec 10 22:20:04 CST 2023, time=2023-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1220774, encodeId=1c181220e7421, content=请问这个期刊接收兽医领域的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc36406249, createdName=ms9000000094430055, createdTime=Wed May 18 22:15:22 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198701, encodeId=44b11198e0136, content=为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EC68C3C3E967114681E7C61FF972B471/100, createdBy=0d342025844, createdName=汤圆-, createdTime=Wed Mar 02 13:20:58 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107493, encodeId=1731110e493d7, content=评审和期刊编辑要求我补实验，就一定要补么，不补行不行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107494, encodeId=db95110e494e4, content=对于审稿人好的意见也要回复么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602494, encodeId=55eb60249406, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：NPJ系列，是新培育出来的，有前途, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 18 13:02:46 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572669, encodeId=a8fa5e26698b, content=已经破5了，超过vaccine，估计疫苗学以后就是这个top了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851026, encodeId=21bf85102651, content=文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec45414146, createdName=ms3214948925389860, createdTime=Thu Apr 25 14:12:58 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2020-06-18 lovetcm

    审稿速度:2.0 | 投稿命中率:75.0
    经验分享：NPJ系列，是新培育出来的，有前途

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2189864, encodeId=39292189864b6, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：vaccine;immunology<br>经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0dc9186564, createdName=ms9000001531261919, createdTime=Wed Feb 28 11:31:59 CST 2024, time=2024-02-28, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2174128, encodeId=949821e41281d, content=审稿速度:24.0 | 投稿命中率:25.0<br>经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e522550600, createdName=1253f878m25(暂无昵称), createdTime=Sun Dec 10 22:20:04 CST 2023, time=2023-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1220774, encodeId=1c181220e7421, content=请问这个期刊接收兽医领域的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc36406249, createdName=ms9000000094430055, createdTime=Wed May 18 22:15:22 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198701, encodeId=44b11198e0136, content=为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EC68C3C3E967114681E7C61FF972B471/100, createdBy=0d342025844, createdName=汤圆-, createdTime=Wed Mar 02 13:20:58 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107493, encodeId=1731110e493d7, content=评审和期刊编辑要求我补实验，就一定要补么，不补行不行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107494, encodeId=db95110e494e4, content=对于审稿人好的意见也要回复么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602494, encodeId=55eb60249406, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：NPJ系列，是新培育出来的，有前途, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 18 13:02:46 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572669, encodeId=a8fa5e26698b, content=已经破5了，超过vaccine，估计疫苗学以后就是这个top了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851026, encodeId=21bf85102651, content=文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec45414146, createdName=ms3214948925389860, createdTime=Thu Apr 25 14:12:58 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-06-21 qsqsqsqs12

    已经破5了，超过vaccine，估计疫苗学以后就是这个top了。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2189864, encodeId=39292189864b6, content=审稿速度:12.0 | 投稿命中率:25.0<br>偏重的研究方向：vaccine;immunology<br>经验分享：Three reviewer; 1 minor 1 positive 1 major revision. Took 8 month totally, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0dc9186564, createdName=ms9000001531261919, createdTime=Wed Feb 28 11:31:59 CST 2024, time=2024-02-28, status=1, ipAttribution=马里兰), GetPortalCommentsPageByObjectIdResponse(id=2174128, encodeId=949821e41281d, content=审稿速度:24.0 | 投稿命中率:25.0<br>经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e522550600, createdName=1253f878m25(暂无昵称), createdTime=Sun Dec 10 22:20:04 CST 2023, time=2023-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1220774, encodeId=1c181220e7421, content=请问这个期刊接收兽医领域的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2fc36406249, createdName=ms9000000094430055, createdTime=Wed May 18 22:15:22 CST 2022, time=2022-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198701, encodeId=44b11198e0136, content=为啥让我小修之后就一直没动静了呀？有没有人有同样的情况？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/EC68C3C3E967114681E7C61FF972B471/100, createdBy=0d342025844, createdName=汤圆-, createdTime=Wed Mar 02 13:20:58 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107493, encodeId=1731110e493d7, content=评审和期刊编辑要求我补实验，就一定要补么，不补行不行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1107494, encodeId=db95110e494e4, content=对于审稿人好的意见也要回复么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:53 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602494, encodeId=55eb60249406, content=审稿速度:2.0 | 投稿命中率:75.0<br>经验分享：NPJ系列，是新培育出来的，有前途, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 18 13:02:46 CST 2020, time=2020-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572669, encodeId=a8fa5e26698b, content=已经破5了，超过vaccine，估计疫苗学以后就是这个top了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=326, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=71a098094, createdName=qsqsqsqs12, createdTime=Fri Jun 21 00:00:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=851026, encodeId=21bf85102651, content=文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=237, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ec45414146, createdName=ms3214948925389860, createdTime=Thu Apr 25 14:12:58 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-04-25 ms3214948925389860

    文章质量相当高，是疫苗领域最好的期刊。分到3区，呵呵，也不知道怎么来分的。

    0

共14条页码: 1/2页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分